Infliximab decreased TNFR2 expression, the nuclear factor κB (NFκB) level, the inducible NO-synthase (iNOS level), and prevented CCH-induced myocardial oxidative stress[114]. This evidence concerns the gene TNFRSF1B and columnar cell hyperplasia of the breast.